Description

Bausch + Lomb’s second quarter 2025 results reflect a mix of solid performance and ongoing strategic challenges. The company’s revenue grew by 3% year-over-year, reaching $1.278 billion, spurred by robust growth in their contact lenses and consumer segments, despite facing headwinds such as the enVista intraocular lens recall and challenges in their U.S. generics business. Positives in this performance include constant currency revenue growth of 3%, which would have been significantly higher at 6% if the enVista recall had been excluded. The Vision Care segment, driven by a 6% increase in consumer and contact lens growth, performed well, highlighting the strength of Bausch + Lomb’s consumer brands. Specifically, the Daily Silicone Hydrogel (SiHy) franchise achieved remarkable growth of 36% in the quarter, underlining the company’s competitive edge in this market. Their comprehensive dry eye portfolio showed substantial growth with LUMIFY, ARTELAC, and Blink all contributing positively.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!